NCT02645851

Brief Summary

Rapid volume expansion using repeated intravenous fluid boluses is a very common intervention performed in the intensive care unit (ICU) in the early days of resuscitation of patients with shock. Once passed the initial phase of resuscitation, the fluid boluses administered fail to effectively increase the patients' cardiac output in about 50% of cases. Pulse pressure changes or stroke volume changes induced by a Passive Leg Raising (PLR) test have acceptable/good ability to predict fluid responsiveness (in terms of cardiac output change) and may be systematically used in patients with persistent shock with the aim of limiting the total amount of fluid administered to patients by avoiding undue fluid boluses. One may suppose that such a volume expansion management policy could impact morbidity and mortality of shocked patients. Among the predictive indices available in clinical practice, the PLR test has the advantages of being usable regardless of the patients' respiratory status and cardiac rhythm. Changes in left ventricular stroke volume during the PLR test perform better that changes in pulse pressure to predict fluid responsiveness. However, in counterpart, pulse pressure changes during PLR can be assessed without the need of other hemodynamic exploration such central venous pressure measurement or cardiac output monitoring. The investigators hypothesized that strategies using either stroke volume changes or pulse pressure changes induced by the PLR test to decide wether a fluid bolus clinically deemed indicated should or should not be administered, may limit the amount of fluid received by the patients during the first 5 days of shock, improve their oxygenation index, and shorten the time passed under mechanical ventilation, as compared to a "liberal" strategy (usual care) that does not use predictive indices of fluid responsiveness.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
98

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 27, 2015

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 5, 2016

Completed
11 days until next milestone

Study Start

First participant enrolled

January 16, 2016

Completed
8.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 4, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 4, 2024

Completed
Last Updated

February 14, 2025

Status Verified

February 1, 2025

Enrollment Period

8.3 years

First QC Date

December 27, 2015

Last Update Submit

February 13, 2025

Conditions

Keywords

Fluid TherapyPlasma SubstitutesFluid Balance

Outcome Measures

Primary Outcomes (1)

  • PaO2/FiO2 ratio changes

    from inclusion to the 24th hour after inclusion

Secondary Outcomes (5)

  • ventilator free days

    ventilator free days between inclusion and the 28th day

  • Catheter-related complications

    from inclusion to the date of intensive care unit discharge, an average of 10 days

  • Fluid balance

    from inclusion to the 7th day

  • Immediate respiratory tolerance of fluid bolus (Yes or No)

    at each fluid bolus administered during the intervention period (from inclusion to 120 hours later)

  • mortality rate

    at 28 days

Study Arms (3)

"PLR-induced SV changes" based strategy

EXPERIMENTAL

During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Stroke Volume (SV) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if SV changes ≥10%, or no administration otherwise. Measurement of beat-to-beat stroke volume by intraarterial pulse contour analysis using the PiCCO system (Pulsion, Germany) will be used to assess stroke volume changes. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.

Drug: fluid bolusDevice: PiCCO system (Pulsion, Germany)Device: Vascular pressure transducers (Edwards Life Science, USA)Other: Passive Leg Raising test

"PLR-induced PP changes" based strategy

EXPERIMENTAL

During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Pulse Pressure (PP) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if PP changes ≥10%, or no administration otherwise. We will perform measurement of intraarterial blood pressure using vascular pressure transducers (Edwards Life Science, USA). Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.

Drug: fluid bolusDevice: Vascular pressure transducers (Edwards Life Science, USA)Other: Passive Leg Raising test

Usual Care

OTHER

During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the fluid bolus will be administered without measurement of any predictive index of fluid responsiveness. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.

Drug: fluid bolusDevice: Vascular pressure transducers (Edwards Life Science, USA)

Interventions

Administration of the fluid bolus if deemed clinically necessary, OR if deemed clinically necessary AND PLR-induced SV or PP changes ≥10%, depending of the Arm the patient is assigned to

Also known as: vascular volume expansion
"PLR-induced PP changes" based strategy"PLR-induced SV changes" based strategyUsual Care

During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Stroke Volume changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced stroke volume change is over 10%; in case stroke volume change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)

"PLR-induced SV changes" based strategy

During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Pulse Pressure changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced Pulse Pressure change is over 10%; in case Pulse Pressure change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)

"PLR-induced PP changes" based strategy"PLR-induced SV changes" based strategyUsual Care

Passive elevation of the legs of the patient, and lying down of the trunk (if patient is in the semi-recumbent position), preferably using electric bed. If not available, elevation of the legs by an assistant to a 45 degrees angle. Effects of Passive Leg Raising on Pulse Pressure or on Stroke Volume are used to assess fluid responsiveness in patients suffering from shock states.

Also known as: Passive elevation of the legs of the patient.
"PLR-induced PP changes" based strategy"PLR-induced SV changes" based strategy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Persistence of arterial hypotension (as defined above) or continuous iv infusion of norepinephrine
  • Patient under invasive mechanical ventilation
  • At least one of the following conditions is present
  • Alteration of consciousness
  • Mottling skin
  • Cyanosis of the extremities despite SaO2\>90%
  • Oliguria defined as urine output below 0.5ml/kg of actual body weight over at least 1 hour
  • Arterial lactate \> 2 mmol/L
  • ScvO2 \< 70%
  • Central venous (internal jugular or subclavian) or femoral venous catheter in place
  • Arterial catheter in place

You may not qualify if:

  • Shock began more than 24 hours ago
  • Age \< 18 yrs.
  • Pregnancy
  • Uncontrolled haemorrhage
  • Intra-aortic balloon counterpulsation in place
  • Patient under veno-arterial extracorporeal membrane oxygenation (V-A ECMO)
  • Cardiogenic pulmonary oedema during the past 24 hours
  • Patient equipped with a cardiac output monitoring device
  • Brain death
  • Moribund patient
  • Traction of a lower limb
  • Amputated lower limb above the ankle level
  • Documented intra-abdominal hypertension
  • \. Cardiac arrest motivating ICU admission or cardiac arrest since admission 14. Patient without social security number 15. Consent refusal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Régional d'Orléans, France

Orléans, 45000, France

Location

Related Publications (7)

  • Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaud P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002 Aug 21;288(7):862-71. doi: 10.1001/jama.288.7.862.

    PMID: 12186604BACKGROUND
  • Annane D, Sebille V, Duboc D, Le Heuzey JY, Sadoul N, Bouvier E, Bellissant E. Incidence and prognosis of sustained arrhythmias in critically ill patients. Am J Respir Crit Care Med. 2008 Jul 1;178(1):20-5. doi: 10.1164/rccm.200701-031OC. Epub 2008 Apr 3.

    PMID: 18388358BACKGROUND
  • Antonelli M, Levy M, Andrews PJ, Chastre J, Hudson LD, Manthous C, Meduri GU, Moreno RP, Putensen C, Stewart T, Torres A. Hemodynamic monitoring in shock and implications for management. International Consensus Conference, Paris, France, 27-28 April 2006. Intensive Care Med. 2007 Apr;33(4):575-90. doi: 10.1007/s00134-007-0531-4.

    PMID: 17285286BACKGROUND
  • Benes J, Chytra I, Altmann P, Hluchy M, Kasal E, Svitak R, Pradl R, Stepan M. Intraoperative fluid optimization using stroke volume variation in high risk surgical patients: results of prospective randomized study. Crit Care. 2010;14(3):R118. doi: 10.1186/cc9070. Epub 2010 Jun 16.

    PMID: 20553586BACKGROUND
  • Boulain T, Achard JM, Teboul JL, Richard C, Perrotin D, Ginies G. Changes in BP induced by passive leg raising predict response to fluid loading in critically ill patients. Chest. 2002 Apr;121(4):1245-52. doi: 10.1378/chest.121.4.1245.

    PMID: 11948060BACKGROUND
  • Boulain T, Garot D, Vignon P, Lascarrou JB, Desachy A, Botoc V, Follin A, Frat JP, Bellec F, Quenot JP, Mathonnet A, Dequin PF; Clinical Research in Intensive Care and Sepsis Group. Prevalence of low central venous oxygen saturation in the first hours of intensive care unit admission and associated mortality in septic shock patients: a prospective multicentre study. Crit Care. 2014 Nov 6;18(6):609. doi: 10.1186/s13054-014-0609-7.

    PMID: 25529124BACKGROUND
  • Boulain T, Boisrame-Helms J, Ehrmann S, Lascarrou JB, Bougle A, Chiche A, Lakhal K, Gaudry S, Perbet S, Desachy A, Cabasson S, Geneau I, Courouble P, Clavieras N, Massanet PL, Bellec F, Falquet Y, Reminiac F, Vignon P, Dequin PF, Meziani F. Volume expansion in the first 4 days of shock: a prospective multicentre study in 19 French intensive care units. Intensive Care Med. 2015 Feb;41(2):248-56. doi: 10.1007/s00134-014-3576-1. Epub 2014 Dec 2.

    PMID: 25447804BACKGROUND

MeSH Terms

Conditions

ShockHypovolemia

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Thierry Boulain, MD

    Centre Hospitalier Régional d'Orléans, France

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 27, 2015

First Posted

January 5, 2016

Study Start

January 16, 2016

Primary Completion

May 4, 2024

Study Completion

May 4, 2024

Last Updated

February 14, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations